Mianserine-fluvoxamine

From Psychiatrienet
Revision as of 12:45, 6 May 2009 by Alexandra (talk | contribs) (Created page with '{{Drugswitch | from = mianserine | to = fluvoxamine | stop = * '''Day 0:''' gradually reduce dosage of mianserine to a maximum of 60 mg/ day. * '''Day 1:''' reduce a dosage o...')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine

Switch medication from mianserine to fluvoxamine.[1] [2]

Nietinrijdenbord.png Stop mianserine
  • Day 0: gradually reduce dosage of mianserine to a maximum of 60 mg/ day.
  • Day 1: reduce a dosage of 60 mg/day to 30 mg/day.
Eenrichtingbord.png Start fluvoxamine
  • Day 1: simultaneously start fluvoxamine in a normal dosage of 50 mg/day.
  • Day 8: stop administration of mianserine and only continue administration of fluvoxamine only.
  • If necessary, increase the dosage of fluvoxamine.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.